NCT07086105View on ClinicalTrials.gov

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

July 1, 2027

Conditions
Metastatic Melanoma
Interventions
DRUG

Adze1.C

Conditionally replicative oncolytic adenovirus expressing CD40L, administered by intratumoural injection in dose escalation cohorts.

Trial Locations (2)

4215

Tasman Oncology Research, Southport

5011

The Queen Elizabeth Hospital, Adelaide

All Listed Sponsors
lead

Adze Biotechnology Australia Pty Ltd

INDUSTRY